The design, synthesis, and evaluation of the biological activity of hydroxamic derivatives of sorafenib
Sorafenib is a multiple tyrosine kinase inhibitor that is used in the treatment of liver and renal cancers. We synthesized the hydroxamic derivatives of sorafenib bearing the pharmacophore elements of zinc-dependent histone deacetylase inhibitors. We uncovered that suppression of cancer cell proliferation by the synthesized hybrid inhibitors critically depends on the structure of the "deacetylase" element.
Authors
- A. A. Kleymenova
- Sergey N. Kochetkov (ORCID: https://orcid.org/0000-0002-7443-6961)
- Natalia F. Zakirova (ORCID: https://orcid.org/0000-0001-9704-6977)
- И. А. Абрамов (ORCID: https://orcid.org/0000-0002-7433-7728)
- Ya. V. Tkachev
- М. В. Козлов (ORCID: https://orcid.org/0000-0002-5994-9099)
- P. S. Galeeva
- V. A. Kleymenova
Institutions
- Engelhardt Institute of Molecular Biology (RU)
- Sechenov University (RU)
Publication Details
- Journal
- Acta Naturae
- Published
- 2025-10-14
- DOI
- https://doi.org/10.32607/actanaturae.27566
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00